Found 997 clinical trials
Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer
Breast cancer participants and their surgical oncologists will be asked their preference regarding radiation therapy before starting endocrine therapy and again post-operatively. They will make a determination regarding radiation therapy as per standard care. The hypothesis is that knowledge of tolerance of endocrine therapy will influence the decision by the …
- 0 views
- 19 Feb, 2024
Effects of Brain Stimulation on Cognition Oscillations and GABA Levels in Schizophrenia
This study has three main goals: (1) To compare the effects of task-engaged versus resting tDCS in order to optimize the impact of tDCS on goal maintenance related neural oscillatory activity and task performance in schizophrenia; (2) To establish the regional specificity of the impact of DLPFC tDCS (compared to …
- 0 views
- 19 Feb, 2024
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.
A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac axis, superior mesenteric artery (SMA)]. In these patients, chemotherapy has been the standard treatment for decades, optionally combined with radiotherapy.
- 0 views
- 19 Feb, 2024
Changing the Culture of Disrespect and Abuse in Maternity Care in Kumasi Ghana
Based on data collected, feasibility will be examined and the RMC-M will be further modified as needed prior to beginning Aim 2. To achieve Aim 2, a two group study design will be used, with one group of midwives receiving training on the RMC- M and the other not receiving …
- 0 views
- 19 Feb, 2024
SBRT for Breast Cancer Oligometastases
If functional imaging (bone scan, PET) were used at staging, changes in the uptake will be used in follow up scans to determine response to treatment and progression. As for SBRT related morbidities, we will use the Common Terminology Criteria for Adverse Events (CTCAE v5) for toxicity reporting and scoring.
- 0 views
- 19 Feb, 2024
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
Six doses of rituximab and will be monitored the week 5 MRD and relapse rate as study outcome. Adding bortezomid during the consolidation:The very early or early bone marrow relapse has low remission rate.
- 0 views
- 19 Feb, 2024
Morphological Parameters of In-stent RESTenosis Assessed and Identified by OCT
The number and clinical lifespan of stents implanted over the last twenty-five years, however, explain the fact that restenosis remains a not unusual clinical problem which is expressed as a recurrence of angina or of an acute coronary syndrome (ACS). The mechanisms involved in this restenosis are multifactorial in nature …
- 0 views
- 19 Feb, 2024
Carotid Doppler and EEOT for Fluid Responsiveness Prediction
New approaches have been recently developed based on changes in respiratory dynamics, such as a transient increase in tidal volume, or a lung recruitment maneuver or an end-expiratory occlusion (EEO) test. The EEO leaded to an increase in venous return, cardiac preload and stroke volume in preload-responsive patients.
- 0 views
- 19 Feb, 2024
1 march 4
The dose of 1-5 x 10xE8 T-cells in Stage 2 will be administered via split dosing: 10% on Day 1 (1-5x10xE7), 30% on Day 2 (3x107-1.5x10xE8), 60% on Day 3 (6x107-3x10xE8). Evaluable subjects are defined as those who were able to receive the viable product at the intended dose level …
- 0 views
- 19 Feb, 2024
- 1 location
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
Around 132 participants will be enrolled in approximately 30 sites worldwide. Risankizumab and ustekinumab are given as a subcutaneous (under the skin) injection. Parts 1, 3, and 4: Risankizumab for 40 weeks with a follow-up call 20 weeks later for a study duration of approximately 65 weeks.
- 0 views
- 19 Feb, 2024